Published in Cancer Imaging on October 04, 2010
Rapid dramatic alterations to the tumor microstructure in pancreatic cancer following irreversible electroporation ablation. Nanomedicine (Lond) (2013) 0.84
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med (2004) 15.10
Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst (2006) 9.91
Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging. Radiology (1988) 8.08
Diffusion-weighted magnetic resonance imaging as a cancer biomarker: consensus and recommendations. Neoplasia (2009) 7.44
Gadolinium--a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant (2006) 7.13
Diffusion-weighted MRI in the body: applications and challenges in oncology. AJR Am J Roentgenol (2007) 6.80
Early detection of regional cerebral ischemia in cats: comparison of diffusion- and T2-weighted MRI and spectroscopy. Magn Reson Med (1990) 4.88
Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology (2007) 4.25
Diffusion-weighted MR imaging of the brain. Radiology (2000) 4.16
Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure? J Urol (2003) 3.58
Measurement of cell density and necrotic fraction in human melanoma xenografts by diffusion weighted magnetic resonance imaging. Magn Reson Med (2000) 3.34
Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma. Proc Natl Acad Sci U S A (2005) 3.15
Combined T2-weighted and diffusion-weighted MRI for localization of prostate cancer. AJR Am J Roentgenol (2007) 3.12
Contrast-induced nephropathy: definition, epidemiology, and patients at risk. Kidney Int Suppl (2006) 2.84
Contrast-media-induced nephrotoxicity: a consensus report. Contrast Media Safety Committee, European Society of Urogenital Radiology (ESUR). Eur Radiol (1999) 2.57
The value of a second transurethral resection in evaluating patients with bladder tumors. J Urol (1999) 2.56
Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging. Radiology (2006) 2.49
Is pelvic lymph node dissection necessary in patients with a serum PSA<10ng/ml undergoing radical prostatectomy for prostate cancer? Eur Urol (2006) 2.32
A study of diffusion-weighted magnetic resonance imaging in men with untreated localised prostate cancer on active surveillance. Eur Urol (2008) 2.25
Effects of cell volume fraction changes on apparent diffusion in human cells. Magn Reson Imaging (2000) 2.06
Renal lesions: characterization with diffusion-weighted imaging versus contrast-enhanced MR imaging. Radiology (2009) 1.94
Predicting and monitoring cancer treatment response with diffusion-weighted MRI. J Magn Reson Imaging (2010) 1.82
Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol (2006) 1.81
Diffusion-weighted magnetic resonance imaging: a potential non-invasive marker of tumour aggressiveness in localized prostate cancer. Clin Radiol (2008) 1.76
The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis. BJU Int (2007) 1.71
Diffusion-weighted MRI in the evaluation of renal lesions: preliminary results. Br J Radiol (2004) 1.69
Renal masses: characterization with diffusion-weighted MR imaging--a preliminary experience. Radiology (2008) 1.67
Validation of an acute ischemic stroke model: does diffusion-weighted imaging lesion volume offer a clinically significant improvement in prediction of outcome? Stroke (2007) 1.65
Endorectal diffusion-weighted imaging in prostate cancer to differentiate malignant and benign peripheral zone tissue. J Magn Reson Imaging (2004) 1.57
Value of diffusion-weighted imaging for the prediction of prostate cancer location at 3T using a phased-array coil: preliminary results. Invest Radiol (2007) 1.57
Extracranial applications of diffusion-weighted magnetic resonance imaging. Eur Radiol (2007) 1.55
Prostate tumor volume measurement with combined T2-weighted imaging and diffusion-weighted MR: correlation with pathologic tumor volume. Radiology (2009) 1.55
Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA. Clin Radiol (2000) 1.54
Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy--results of ACRIN prospective multi-institutional clinicopathologic study. Radiology (2009) 1.48
Functional MR imaging of prostate cancer. Radiographics (2007) 1.48
Abdomen: diffusion-weighted MR imaging with pulse-triggered single-shot sequences. Radiology (2002) 1.45
Apparent diffusion coefficient values in peripheral and transition zones of the prostate: comparison between normal and malignant prostatic tissues and correlation with histologic grade. J Magn Reson Imaging (2008) 1.43
Diffusion imaging of the prostate at 3.0 tesla. Invest Radiol (2006) 1.40
Dynamic contrast-enhanced MRI in normal and abnormal prostate tissues as defined by biopsy, MRI, and 3D MRSI. Magn Reson Med (2005) 1.38
Sensitivity of MR diffusion measurements to variations in intracellular structure: effects of nuclear size. Magn Reson Med (2009) 1.34
Diffusion-weighted imaging of prostate cancer. J Comput Assist Tomogr (2005) 1.30
Prostate cancer: evaluation of vascular characteristics with dynamic contrast-enhanced T1-weighted MR imaging--initial experience. Radiology (2004) 1.29
Localization of prostate cancer using 3T MRI: comparison of T2-weighted and dynamic contrast-enhanced imaging. J Comput Assist Tomogr (2005) 1.29
Urinary bladder cancer: diffusion-weighted MR imaging--accuracy for diagnosing T stage and estimating histologic grade. Radiology (2009) 1.28
Preliminary results for characterization of pelvic lymph nodes in patients with prostate cancer by diffusion-weighted MR-imaging. Invest Radiol (2010) 1.22
Diffusion-weighted MR imaging in the evaluation of renal tumours. J Exp Clin Cancer Res (2004) 1.19
Magnetic resonance imaging and spectroscopic imaging of prostate cancer. J Urol (2003) 1.18
Field strength and diffusion encoding technique affect the apparent diffusion coefficient measurements in diffusion-weighted imaging of the abdomen. Invest Radiol (2010) 1.17
Magnetic resonance diffusion characteristics of histologically defined prostate cancer in humans. Magn Reson Med (2009) 1.17
Prediction of locally recurrent prostate cancer after radiation therapy: incremental value of 3T diffusion-weighted MRI. J Magn Reson Imaging (2009) 1.17
Extracapsular extension of pelvic lymph node metastases from urothelial carcinoma of the bladder is an independent prognostic factor. J Clin Oncol (2005) 1.14
An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer: results on 4298 cases. Urology (1998) 1.10
Evaluation of the potential of diffusion-weighted imaging in prostate cancer detection. Acta Radiol (2007) 1.06
Bladder tumour staging: comparison of diffusion- and T2-weighted MR imaging. Eur Radiol (2009) 1.06
T1 hyperintense renal lesions: characterization with diffusion-weighted MR imaging versus contrast-enhanced MR imaging. Radiology (2009) 1.05
Improved magnetic resonance imaging detection of prostate cancer in a transgenic mouse model. Cancer Res (2002) 1.05
Monitoring prostate thermal therapy with diffusion-weighted MRI. Magn Reson Med (2008) 1.04
Age-related and zonal anatomical changes of apparent diffusion coefficient values in normal human prostatic tissues. J Magn Reson Imaging (2008) 1.03
Diffusion-weighted imaging of the parotid gland: Influence of the choice of b-values on the apparent diffusion coefficient value. J Magn Reson Imaging (2004) 1.03
Imaging and staging of transitional cell carcinoma: part 1, lower urinary tract. AJR Am J Roentgenol (2009) 0.97
Challenges in the treatment of bladder cancer. Ann Oncol (2006) 0.95
Apparent diffusion coefficient of the prostate in men prior to biopsy: determination of a cut-off value to predict malignancy of the peripheral zone. NMR Biomed (2007) 0.92
Diffusion tensor magnetic resonance imaging of prostate cancer. Invest Radiol (2007) 0.89
ADC value and diffusion tensor imaging of prostate cancer: changes in carbon-ion radiotherapy. J Magn Reson Imaging (2008) 0.87
Angiogenesis inhibitors in the treatment of prostate cancer. Expert Opin Pharmacother (2010) 0.86
Preoperative T staging of urinary bladder cancer: does diffusion-weighted MRI have supplementary value? AJR Am J Roentgenol (2009) 0.86
Novel therapeutics for metastatic renal cell carcinoma. Cancer (2009) 0.84
Diffusion-weighted MR imaging of the kidneys and the urinary tract. Magn Reson Imaging Clin N Am (2008) 0.84
Radiologic diagnosis and staging of renal and bladder cancer. Semin Roentgenol (2006) 0.79
Treatment of muscle-invasive bladder cancer. Expert Rev Anticancer Ther (2007) 0.78
Superficial bladder cancer: part 2. Management. Expert Rev Anticancer Ther (2007) 0.78
The role of imaging in the surveillance of urologic malignancies. Urol Clin North Am (2006) 0.76